Recently public company Tarsus Pharmaceuticals Inc. unveiled positive data from a Phase IIb/III study in eyelash mites on 21 June for an antiparasitic medicine initially developed to prevent tick and flea infestation in domestic animals such as dogs. In an interview, Tarsus CEO Bobak Azamian explained that there is precedent in both antiparasitic and ophthalmic medicine to adapt compounds initially developed for animal health uses.
Tarsus Uses Veterinary Drug To Target Unserved Ocular Disease
With success on multiple endpoints in its first pivotal trial of lotilaner in Demodex blepharitis, Tarsus is working to bring the veterinary antiparasitic drug to market in multiple human indications.
More from Strategy
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.